Cannabis, Medical

Developed for: amyotrophic lateral sclerosis · anxiety · autism · bipolar disorder · cancer · COVID-19 · Crohn disease · depressive disorder
+15 more
· epilepsy · fibromyalgia · glaucoma · hepatitis C virus infection · HIV infectious disease · insomnia · multiple sclerosis · Parkinson disease · post-traumatic stress disorder · sickle cell disease · substance-related disorder · Tourette syndrome · traumatic brain injury · traumatic encephalopathy · ulcerative colitis
Investigated by: OMNI Medical Services, LLC

today NCT03944447 · Ph 2

20192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT03944447	Dec 2018 → Dec 2025	COVID-19, Crohn disease, HIV infectious disease, Parkinson disease +19	OMNI Medical Services, LLC	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Cannabis, Medical	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03944447 ↗